Sebastian C. Tume
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sebastian C. Tume has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Iki Adachi
Division of Congenital Heart Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, 6651 Main St, Houston, TX 77030
3 shared publications - Aamir Jeewa
Labatt Family Heart Centre, Division of Pediatric Cardiology, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Canada
2 shared publications - Joseph A. Spinner
Texas Children's Hospital Houston Texas USA
2 shared publications - Muhammad Shezad
The Heart Institute, Cincinnati Children's Hospital Medical Center
2 shared publications - Sabrina Law
Morgan Stanley Children's Hospital of New York Presbyterian
2 shared publications - Ahmed Sameh Said
Washington University in St. Louis
1 shared publication
Latest Publications
- 6 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (8) , 986-997
Validation of Minimally Invasive and Noninvasive Hemodynamic Monitoring in Adolescents: The Pediatric Cardiac Output Monitoring Observational (POGO) Study
Objectives: Minimally invasive cardiac output (CO) monitoring technologies lack validation in the adolescent population. We aimed to test the accuracy and precision of the FloTrac arterial pressure cardiac output (APCO) and ClearSight photoplethysmography cardiac output (PPGCO; Edwards Lifesciences, Irvine, CA) technologies in adolescents undergoing elective cardiac catheterization. Design: Prospective, single-arm, nonrandomized, observational study. Setting: Cardiac catheterization laboratory at three freestanding pediatric hospitals in the United States. Patients: Adolescent patients 12–18 years of age undergoing surveillance cardiac catheterization after heart transplantation. Interventions: Swan-Ganz pulmonary artery catheterization with the intermittent thermodilution CO (iCO) technique was used as the gold standard for CO measurements. APCO was measured using an existing femoral arterial sheath, and PPGCO was measured utilizing a volumetric cuff placed on the finger of the upper extremities. Two sets of simultaneous iCO, APCO, and PPGCO measurements were compared. Bias and level of concordance were assessed using Bland-Altman analysis. Measurements and Main Results: Out of the 89 subjects enrolled, 73 underwent measurements and provided a total of 60 sets of measurements for each device. The median age was 16 years (interquartile range [IQR], 14–17 yr) with a median body surface area of 1.6 m 2 (IQR, 1.5–1.8 m 2 ). The median averaged intermittent cardiac index was 2.7 L/min/m 2 (IQR, 2.3–3.1 L/min/m 2) . FloTrac APCO mean bias was 0.32 L/min/m 2 (IQR, 0.20–0.44 L/min/m 2 ) with a precision of 0.70 L/min/m 2 (IQR, 0.58–0.82 L/min/m 2 ). ClearSight PPGCO mean bias was 0.28 L/min/m 2 (95% CI, 0.16–0.41 L/min/m 2 ) with a precision of 0.71 L/min/m 2 (95% CI, 0.59–0.84 L/min/m 2 ). No serious adverse events were reported related to the devices. Conclusions: The minimally and noninvasive CO measurements with FloTrac and ClearSight APCO show acceptable bias and precision under standardized elective clinical conditions in an adolescent pediatric population, making them useful tools in the routine clinical management of critically ill children.
- 6 August 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 27 (8) , 986-997
Validation of Minimally Invasive and Noninvasive Hemodynamic Monitoring in Adolescents: The Pediatric Cardiac Output Monitoring Observational (POGO) Study
Objectives: Minimally invasive cardiac output (CO) monitoring technologies lack validation in the adolescent population. We aimed to test the accuracy and precision of the FloTrac arterial pressure cardiac output (APCO) and ClearSight photoplethysmography cardiac output (PPGCO; Edwards Lifesciences, Irvine, CA) technologies in adolescents undergoing elective cardiac catheterization. Design: Prospective, single-arm, nonrandomized, observational study. Setting: Cardiac catheterization laboratory at three freestanding pediatric hospitals in the United States. Patients: Adolescent patients 12–18 years of age undergoing surveillance cardiac catheterization after heart transplantation. Interventions: Swan-Ganz pulmonary artery catheterization with the intermittent thermodilution CO (iCO) technique was used as the gold standard for CO measurements. APCO was measured using an existing femoral arterial sheath, and PPGCO was measured utilizing a volumetric cuff placed on the finger of the upper extremities. Two sets of simultaneous iCO, APCO, and PPGCO measurements were compared. Bias and level of concordance were assessed using Bland-Altman analysis. Measurements and Main Results: Out of the 89 subjects enrolled, 73 underwent measurements and provided a total of 60 sets of measurements for each device. The median age was 16 years (interquartile range [IQR], 14–17 yr) with a median body surface area of 1.6 m 2 (IQR, 1.5–1.8 m 2 ). The median averaged intermittent cardiac index was 2.7 L/min/m 2 (IQR, 2.3–3.1 L/min/m 2) . FloTrac APCO mean bias was 0.32 L/min/m 2 (IQR, 0.20–0.44 L/min/m 2 ) with a precision of 0.70 L/min/m 2 (IQR, 0.58–0.82 L/min/m 2 ). ClearSight PPGCO mean bias was 0.28 L/min/m 2 (95% CI, 0.16–0.41 L/min/m 2 ) with a precision of 0.71 L/min/m 2 (95% CI, 0.59–0.84 L/min/m 2 ). No serious adverse events were reported related to the devices. Conclusions: The minimally and noninvasive CO measurements with FloTrac and ClearSight APCO show acceptable bias and precision under standardized elective clinical conditions in an adolescent pediatric population, making them useful tools in the routine clinical management of critically ill children.
- 10 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1668-1671
Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network
- 10 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1668-1671
Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network
- 12 May 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (7) , e935-e937
Point-of-Care Ultrasound in Pediatric Resuscitation? What’s All the Rapid Ultrasound for Shock and Hypotension About?
- 12 May 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (7) , e935-e937
Point-of-Care Ultrasound in Pediatric Resuscitation? What’s All the Rapid Ultrasound for Shock and Hypotension About?
- 5 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (7) , 602-608
Transcatheter Axial Pump Use in Pediatric Patients on Veno-Arterial Extracorporeal Membrane Oxygenation: An ACTION Collaborative Experience
We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative database, we conducted a retrospective, multicenter study of all patients with cardiogenic shock requiring VA-ECMO support with subsequent Impella implant between October 2014 and December 2021. The primary outcome was defined as death while on Impella support. Secondary outcomes were recovery, transplantation, and transition to durable ventricular assist device (VAD) at the time of Impella explantation. Adverse events were defined according to the ACTION registry criteria. Twenty subjects were supported with Impella; Impella 2.5 (n = 3), CP (n = 12), 5.0/5.5 (n = 5). The median Interquartile range (IQR) age, weight, and body surface area at implantation were 15.6 years (IQR = 13.9–17.2), 65.7 kg (IQR = 53.1–80.7), and 1.74 m2 (IQR = 1.58–1.98). Primary cardiac diagnoses were dilated cardiomyopathy/myocarditis in nine (45%), congenital heart disease in four (20%), graft failure/rejection in four (20%), and three (15%) others. Most common adverse events included hemolysis (50%) and bleeding (20%). There were two deaths (10%) in the cohort. Nine patients (45%) were explanted for recovery, eight (40%) were transitioned to a durable VAD, and one (5%) underwent heart transplantation. Impella percutaneous pump support should be considered in the older pediatric population supported with peripheral VA-ECMO, as a means of left heart decompression, and a strategy to come off ECMO to achieve endpoints of myocardial recovery, transition to a durable VAD, or transplantation.
- 5 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (7) , 602-608
Transcatheter Axial Pump Use in Pediatric Patients on Veno-Arterial Extracorporeal Membrane Oxygenation: An ACTION Collaborative Experience
We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative database, we conducted a retrospective, multicenter study of all patients with cardiogenic shock requiring VA-ECMO support with subsequent Impella implant between October 2014 and December 2021. The primary outcome was defined as death while on Impella support. Secondary outcomes were recovery, transplantation, and transition to durable ventricular assist device (VAD) at the time of Impella explantation. Adverse events were defined according to the ACTION registry criteria. Twenty subjects were supported with Impella; Impella 2.5 (n = 3), CP (n = 12), 5.0/5.5 (n = 5). The median Interquartile range (IQR) age, weight, and body surface area at implantation were 15.6 years (IQR = 13.9–17.2), 65.7 kg (IQR = 53.1–80.7), and 1.74 m2 (IQR = 1.58–1.98). Primary cardiac diagnoses were dilated cardiomyopathy/myocarditis in nine (45%), congenital heart disease in four (20%), graft failure/rejection in four (20%), and three (15%) others. Most common adverse events included hemolysis (50%) and bleeding (20%). There were two deaths (10%) in the cohort. Nine patients (45%) were explanted for recovery, eight (40%) were transitioned to a durable VAD, and one (5%) underwent heart transplantation. Impella percutaneous pump support should be considered in the older pediatric population supported with peripheral VA-ECMO, as a means of left heart decompression, and a strategy to come off ECMO to achieve endpoints of myocardial recovery, transition to a durable VAD, or transplantation.
- 24 December 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 166 (6) , 1756-1763.e2
Temporary ventricular assist device support with a catheter-based axial pump: Changing the paradigm at a pediatric heart center
- 24 December 2022
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 166 (6) , 1756-1763.e2
Temporary ventricular assist device support with a catheter-based axial pump: Changing the paradigm at a pediatric heart center
- 12 December 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (5) , 637-644
Ventricular assist device support for failing Glenn circulation: Impact of concomitant Fontan completion in select patients
- 12 December 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (5) , 637-644
Ventricular assist device support for failing Glenn circulation: Impact of concomitant Fontan completion in select patients
- 23 May 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 64 (3) , e115-e121
Provider Perceptions for Withdrawing Life Sustaining Therapies at a Large Pediatric Hospital
- 23 May 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 64 (3) , e115-e121
Provider Perceptions for Withdrawing Life Sustaining Therapies at a Large Pediatric Hospital
- 11 January 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (9) , 1036-1043
“Compassionate” Cases of the Jarvik 2015 Ventricular Assist Device
The Jarvik 2015 Ventricular Assist Device (VAD) (Jarvik Inc, New York, NY) is the first and currently only continuous-flow VAD specifically designed for small children, and it is being evaluated in the so-called Pump for Kids, Infants, and Neonates (PumpKIN) trial. Due to the strict inclusion criteria of the trial, there have been a group of patients who failed to meet the criteria and therefore received the Jarvik 2015 VAD under the designation of “compassionate use.” This is the same phenomenon seen previously during the Berlin Heart EXCOR trial. While we await the results of the PumpKIN trial, which will report the device performance in a strictly selected population, the compassionate use cases represent actual “real world” experiences. We describe herein our experience of two compassionate use cases. In particular, this report has a special emphasis on the power consumption and hemolysis and inflammatory lab profile of the Jarvik 2015 VAD as hemocompatibility was the primary focus of the developmental and the preclinical phases.
- 11 January 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (9) , 1036-1043
“Compassionate” Cases of the Jarvik 2015 Ventricular Assist Device
The Jarvik 2015 Ventricular Assist Device (VAD) (Jarvik Inc, New York, NY) is the first and currently only continuous-flow VAD specifically designed for small children, and it is being evaluated in the so-called Pump for Kids, Infants, and Neonates (PumpKIN) trial. Due to the strict inclusion criteria of the trial, there have been a group of patients who failed to meet the criteria and therefore received the Jarvik 2015 VAD under the designation of “compassionate use.” This is the same phenomenon seen previously during the Berlin Heart EXCOR trial. While we await the results of the PumpKIN trial, which will report the device performance in a strictly selected population, the compassionate use cases represent actual “real world” experiences. We describe herein our experience of two compassionate use cases. In particular, this report has a special emphasis on the power consumption and hemolysis and inflammatory lab profile of the Jarvik 2015 VAD as hemocompatibility was the primary focus of the developmental and the preclinical phases.